Specifically, intracerebroventricular administration of HCRT acutely increases Aβ peptide levels in the interstitial space of the hippocampus and cortex, while acute administration of a HCRT antagonist to AD transgenic mice lowers Aβ peptide levels, and chronic HCRT antagonism reduces amyloid plaque burden (Kang et al., 2009). The gene discussed is HCRT; the disease is Alzheimer disease.